Hospital Shares Plunge
Supreme Court Drug-Markup Scrutiny Wipes ₹248 Billion From Indian Healthcare Stocks
Anonymous
Key Points
1
The sell-off wiped about 248 billion rupees ($2.6 billion) from the market value of Indian healthcare stocks, and the BSE Hospitals Index fell 5% on Wednesday.
2
The court’s questions extended to medical devices and to why non-scheduled medicines are excluded from the price-control regime under the Drugs (Prices Control) Order.
3
The weakness persisted into October 1: Apollo fell 2.3%, Max Healthcare 2.2% and Fortis 2.2% in early trade, even as the Nifty Healthcare index was down just 0.4%.
4
Choice Equity Broking analyst Deepika Murarka characterized the market reaction as largely sentiment-driven because the court proceedings had not produced a finalized policy, while warning that price limits could affect pharmacy revenue at large hospital groups.
Indian healthcare stocks tumbled after the Supreme Court questioned whether hospitals unfairly mark up medicine prices. The sell-off erased ₹248 billion ($2.6 billion) in market value on Wednesday, with the BSE Hospitals Index dropping 5% Medical Buyer. The court asked the government to examine allegations that hospitals force patients to buy drugs from their own pharmacies at inflated prices.
Apollo Hospitals, Max Healthcare, and Fortis Healthcare were hit hardest, with shares falling 2.2% to 2.3% in early trading on October 1 Moneycontrol. The court raised the possibility of capping medicine margins across the board, but no final policy has been decided yet.
Why Investors Got Spooked by Court Questions
Hospital pharmacy sales are highly profitable. When courts suggest capping markups or banning forced pharmacy use, investors worry that revenue will shrink Medical Buyer. The Supreme Court specifically questioned steep cancer drug markups and asked why hospitals require patients to use designated pharmacies instead of buying medicine elsewhere Economic Times.
What the Court Actually Asked the Government
The Supreme Court did not issue a ban or set new rules—it asked questions. The court wanted the government to examine whether hospitals illegally require patients to buy medicine from in-house pharmacies Moneycontrol. It also raised concerns about medical devices and non-scheduled medicines that fall outside existing price-control rules Moneycontrol.
Analysts Say the Panic May Be Premature
Choice Equity Broking analyst Deepika Murarka called the market reaction "largely sentiment-driven." No actual policy has been finalized, and court proceedings can take months or years Medical Buyer. However, Murarka warned that if price limits do pass, pharmacy revenue at large hospital groups could be meaningfully reduced.
Hospital Chains Face Pressure Into October
The weakness in healthcare stocks persisted into October 1. Apollo fell 2.3%, Max Healthcare dropped 2.2%, and Fortis slid 2.2% in early trade Moneycontrol. By contrast, the broader Nifty Healthcare Index was down just 0.4%, showing the hit was concentrated among large hospital operators rather than spreading across all healthcare stocks.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
14
Articles
24
Reach
38
A
AnonymousAuthor
